Servatus Limited, an Australian biopharmaceutical company delivering leading novel autoimmune and microbiome therapies, is pleased to announce the appointment of Eilis Quinn to its Board as Non-Executive Director.
Eilis Quinn brings more than 25 years of experience working within biotechnology companies across multiple international markets. She is currently the General Manager of Australia and New Zealand for Jazz Pharmaceuticals, a global pharmaceutical company specialising in oncology and neuroscience. Prior to this, she held senior positions within Vertex Pharmaceuticals, including Senior Director of the Global Pipeline Division, leading the global commercial team.
The appointment adds further commercial expertise to the Servatus Board as the Company rapidly advances clinical programs for its live biotherapeutics products. Trials are currently in progress or in planning across the areas of IBSc, insomnia, rheumatoid arthritis and other autoimmune diseases.
Dr Wayne Finlayson, CEO of Servatus said: "This is an important Board appointment for Servatus as Eilis brings extensive commercial leadership experience within the global biotech and pharmaceutical industries. Her background complements and further strengthens the capabilities of our Board, and we look forward to benefiting from her many years of experience in big pharma across various international markets.
Eilis Quinn said: "As one of the leading companies globally in the microbial biotherapeutics space, I am very pleased to be joining the Servatus Board and look forward to using my expertise to inform global commercialisation strategies."
Eilis has a Master of Arts (MA) Biotechnology, Law and Ethics, from the University of Sheffield, a Master of Science (MSc) Biomedical Sciences, University of Westminster, London, UK and a Bachelor of Science (BSc) Biomedical Sciences, from University of Ulster, Ireland.
Key Facts:
- As General Manager of global pharmaceutical company, Jazz Pharmaceuticals, Eilis Quinn brings extensive commercial and pharmaceutical acumen to the Servatus board
- Eilis Quinn has over 20 years of experience in the healthcare industry across multiple markets, leading business and commercial strategy development for major industry players
- Appointment further builds Servatus' product development and commercialisation expertise for its global biotherapeutics programs
About us:
Servatus Ltd is an unlisted public biopharmaceutical company focused on creating safe, effective, and reliable microbiome-based therapeutic drugs to treat several chronic and debilitating autoimmune diseases, as well as non-antibiotic treatments for bacterial infections.
In addition to drug research and development, and ongoing clinical trials, Servatus also owns a state-of-the-art production facility. This facility means Servatus is able to oversee all aspects of the research development and production pipeline and ensure that its live microbial biotherapeutic drug candidates are made to the highest-standard and specifications, and removes the logistical uncertainty often associated with outsourcing manufacturing.
